re: sgw / cabot review/sabre Its Greenbushes that your guys are interested in anyway Sabre isnt it.Why buy Wodgina(unless the SGW assets are to be sold as a complete entity)when its nowhere near HDNs ground.Greenbushes is the better plant for large output but Wodgina is the more viable combination of mine and plant which brings you back to HDN having to find some decent tantalum resource to feed Greenbushes.
Cabots knows Wodginas the better mine and thats why they hold the security over the mine.Put that together with Cabots lack of cooperation with regards to the arbitration(SGW administrators have been in talks with Cabots trying sort out the contract price for months with no result)and it seems that SGW administrators are caught between a rock and a hard place.
What will be the result?
Time can only tell,but bear in mind there are only 2 main consumers of tantalum and Starks have already signed up for their requirement from Greenbushes so theres only one company thats likely to want 500Klbs of Ta2O5
d.
- Forums
- ASX - By Stock
- SP8
- sgw / cabot review - gip status
sgw / cabot review - gip status, page-9
-
-
- There are more pages in this discussion • 31 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SP8 (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.054M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 3707590 | 0.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.8¢ | 523176 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 3707590 | 0.007 |
7 | 4920000 | 0.006 |
5 | 2960000 | 0.005 |
3 | 6300000 | 0.004 |
2 | 1400000 | 0.003 |
Price($) | Vol. | No. |
---|---|---|
0.008 | 523176 | 5 |
0.009 | 2145158 | 6 |
0.010 | 2035104 | 6 |
0.011 | 3175500 | 3 |
0.012 | 135607 | 2 |
Last trade - 16.12pm 15/07/2024 (20 minute delay) ? |
Featured News
SP8 (ASX) Chart |
Day chart unavailable
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online